EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Hydreight Technologies Inc (NURS) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Hydreight Technologies Inc C$0.59, price C$3.10, upside -81.1%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CA

HT Hydreight Technologies Inc logo Some data Sep 23, 2026

Hydreight Technologies Inc

NURS · V

Weakest SetupStrongly overvalued and low quality.

!Fair value C$0.5865 · Strongly overvalued (−81%)
!Quality 37/100
!Expensive Growth (revenue 5y +139.1 %/yr)
!Thin margins · 7.6% net margin (TTM)
!Low debt · negative free cash flow
!Mixed vs. peers (5/12)
!Moderate moat 55/100
!Evidence only medium, so the estimate is less certain
Watch Hydreight Technologies Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$5.36 C$0.2000 Fair Value C$0.5865 Dec 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

46‑month range C$0.2000 – C$5.36 · fair‑value band C$0.4420 – C$0.7395 · the C$3.10 price screens above the C$0.5865 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Hydreight Technologies in your weekly email

Every Wednesday you see whether Hydreight Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hydreight Technologies Inc. operates in the digital health technology sector in the United States. The company develops a proprietary telemedicine service that allows users to book confidential health and wellness, and/or medical services through a mobile application.

Show more

Hydreight Technologies Inc. operates in the digital health technology sector in the United States. The company develops a proprietary telemedicine service that allows users to book confidential health and wellness, and/or medical services through a mobile application. It also provides consulting and advice in setting up health and wellness services, including assistance with finding experienced advisors in the areas of medical and privacy law, among others; medical liability insurance; pharmaceutical IV programs vetted by duly licensed pharmacists; procedural guides with respect to various services, such as a range of IV therapy treatments, GLP1, NAD, Botox, and fillers; and hiring, on-boarding, training, marketing, branding, payroll, and other accounting services. In addition, the company offers an online pharmacy, which allows its network of medical practitioners to purchase pharmacy products from federally regulated pharmacies. Hydreight Technologies Inc. is headquartered in Las Vegas, Nevada.

Stock analysis

Hydreight Technologies Inc (NURS) currently trades at C$3.10, while our model-based Fair Value estimate is C$0.5865, implying the stock looks roughly 428.5% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of C$1.47 per share, and 0 of the 15 models we run sit above the C$3.10 price.

Bear case: the Asset-Based group reads lowest at C$0.2500, and 15 of the 15 models stay below the price. Evidence for this calculation is medium.

Scenario range: C$0.4420 (bear) to C$0.7395 (bull), the price of C$3.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Hydreight Technologies Inc reported revenue of C$35.4M in FY2025 versus C$1.2M in FY2021, a compound +133.1%/yr. Reported net income was C$1.7M in FY2025.

Key figures

Market cap C$219M (≈ $155M) · P/E ratio 34.4 · P/S ratio 1.65 · EPS (TTM) C$0.0900 · Net margin 4.8% · Return on equity 21.5% · Return on assets (EBIT) −42.1% · Operating margin 11.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −81%, NURS screens richer than that median.

Fair Value models

Bear C$0.4420 Fair Value C$0.5865 Bull C$0.7395
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (C$0.0661 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income C$0.2800 C$0.2900 C$0.3000 74
Owner Earnings C$0.3600 C$0.5800 C$0.9600 72
EPV C$0.3700 C$0.4000 C$0.4200 71
All 15 models by family
DCF Models
Owner Earnings C$0.3600 C$0.5800 C$0.9600 72
Earnings-Based
Graham-Dodd C$0.2100 C$1.50 C$2.10 61
Lynch FV C$0.7700 C$1.11 C$1.44 59
PEG = 1.0 C$0.7700 C$1.11 C$1.44 55
EPV C$0.3700 C$0.4000 C$0.4200 71
Multiples
P/E Multiple C$0.5200 C$0.6900 C$0.8700 63
P/S Multiple C$0.4000 C$0.5400 C$0.6700 58
P/B Multiple C$0.4000 C$0.5400 C$0.6700 55
EV/EBIT C$0.6600 C$0.8400 C$1.01 66
EV/EBITDA C$0.6600 C$0.8300 C$1.01 67
EV/Revenue C$0.5100 C$0.6700 C$0.8300 54
Asset-Based
NCAV (Graham) C$0.1800 C$0.2500 C$0.3700 54
Economic Profit
Residual Income C$0.2800 C$0.2900 C$0.3000 74
ROIC Compounder C$0.3700 C$0.4400 C$0.4900 70
Growth Earnings
Growth-Adj P/E C$1.03 C$1.47 C$1.91 65

Open the full fair value analysis →

Notify me when NURS reaches fair value

Put NURS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 37 · Market factors (momentum, volatility) 28

Profitability 47
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 78
Balance sheet, leverage, solvency risk
Investment 44
Disciplined investing over empire-building
Low Volatility 41
Calm price path (market factor)
Momentum 28
Price trend over the last 3–12 months (market factor)
52W Momentum 12
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+120.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+102.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+139.1%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−51.0% (2020) → 6.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

NURS screens 429% overvalued. Compare with Veeva Systems Inc →

Compare Hydreight Technologies Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 135 stocks

Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −81% · Bottom 25%
Profitability
Return on equity (TTM) 22% · Top 25%
Return on assets 9% · Top 25%
Net margin (TTM) 8% · Above median
Operating margin (TTM) 12% · Above median
Growth and dividend
Revenue growth 449% · Top 25%
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (TTM) 34.4× · Pricier than median
P/B 7.88× · Priciest 25%
P/S (TTM) 2.78× · Pricier than median
EV/EBITDA 30.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)100 · sector 34
PAST (return on equity)86 · sector 4
HEALTH (low debt)79 · sector 98
DIVIDEND (yield)0 · sector 46

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $260.91 $287.00 +10%
Pro Medicus Limited PME A$161.31 A$64.50 −60%
BrightSpring Health Services, Inc BTSG $56.55 $26.07 −54%
HealthEquity, Inc HQY $91.75 $100.93 +10%
Hinge Health, Inc HNGE $94.15 $51.66 −45%
10x Genomics, Inc TXG $80.70 $21.71 −73%
Waystar Holding WAY $25.63 $28.19 +10%
XtalPi Holdings 2228 HK$8.39 HK$1.50 −82%
Doximity, Inc DOCS $26.51 $31.41 +18%
Privia Health Group PRVA $19.46 $5.26 −73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hydreight Technologies Inc · Fair Value
C$0.5865 −429%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Hydreight Technologies Inc Fair Value". https://www.fairvalue-calculator.com/stock/NURS

Frequently asked questions

Is Hydreight Technologies Inc (NURS) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of C$0.5865 versus a price of C$3.10, about −81% upside (overvalued).
What is the fair value of NURS?
Our model-based fair value for Hydreight Technologies Inc is C$0.5865 (as of Sep 23, 2026), built from audited fundamentals. The current price: C$3.10.
What is the quality score of NURS?
Hydreight Technologies Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hydreight Technologies Inc (NURS)?
Our model-based price target is the fair value of C$0.5865 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario C$0.4420, optimistic scenario C$0.7395. It is a calculation from audited fundamentals, not an analyst target.
What is the Hydreight Technologies Inc stock forecast for 2026?
Our models put fair value at C$0.5865, about −81% upside versus a price of C$3.10 (overvalued). Cautious scenario C$0.4420, optimistic scenario C$0.7395. The calculation is refreshed regularly with new filings.
What is the revenue of Hydreight Technologies Inc (NURS)?
Hydreight Technologies Inc reported trailing-twelve-month revenue of about C$55.8M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Hydreight Technologies Inc (NURS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hydreight Technologies Inc it is C$0.5865 per share (as of Sep 23, 2026), against a price of C$3.10. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Hydreight Technologies Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, NURS trades above its calculated fair value: price C$3.10, fair value C$0.5865, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NURS?
No. The price is what the market pays today (C$3.10); the fair value is what the company's own numbers justify (C$0.5865). For Hydreight Technologies Inc the two are C$2.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hydreight Technologies Inc worth?
The market values Hydreight Technologies Inc at about C$219M (market capitalisation, as of Sep 23, 2026). Per share that is C$3.10; our models calculate a fair value of C$0.5865 per share.
What do the bullish and bearish scenarios say about NURS?
Our models span a range for Hydreight Technologies Inc: cautious scenario C$0.4420, base C$0.5865, optimistic C$0.7395 per share (as of Sep 23, 2026, price C$3.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NURS?
Hydreight Technologies Inc trades at a price-to-earnings ratio of 34.4 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$0.5865 is built from several models across several years. Other multiples: P/B 7.9, P/S 2.8, EV/EBITDA 30.2.
How solid is the balance sheet of Hydreight Technologies Inc (NURS)?
Balance-sheet figures for Hydreight Technologies Inc (as of Sep 23, 2026): return on equity 21.5%, debt of 0.42 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is NURS from its 52-week high?
Hydreight Technologies Inc trades at C$3.10, about 42% below its 52-week high of C$5.36 and 30% above the low of C$2.39 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.5865 is for.
Which stocks are comparable to Hydreight Technologies Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hydreight Technologies Inc stock attractive at the current price?
The data as of Sep 23, 2026: price C$3.10, calculated fair value C$0.5865 (−81%), Quality Score 37/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NURS calculated?
We run Hydreight Technologies Inc through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of C$0.5865, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Hydreight Technologies Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hydreight Technologies Inc (NURS)?
The closing price on Sep 23, 2026 was C$3.10. Our model-based fair value is C$0.5865, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hydreight Technologies Inc right now?
The price sits above even our optimistic bull case (C$0.7395). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Hydreight Technologies Inc

How large is the market capitalisation of Hydreight Technologies Inc (NURS)?
The market capitalisation of Hydreight Technologies Inc is C$219M (≈ $155M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hydreight Technologies Inc (NURS)?
The price-to-sales ratio of Hydreight Technologies Inc is 1.65 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hydreight Technologies Inc (NURS)?
Earnings per share at Hydreight Technologies Inc are C$0.0900 (price ÷ EPS = P/E 34.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hydreight Technologies Inc (NURS)?
The net margin of Hydreight Technologies Inc is 4.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hydreight Technologies Inc (NURS)?
The return on equity (ROE) of Hydreight Technologies Inc is 21.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hydreight Technologies Inc (NURS)?
On an EBIT basis the return on assets of Hydreight Technologies Inc is −42.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hydreight Technologies Inc (NURS)?
The operating margin of Hydreight Technologies Inc is 11.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hydreight Technologies Inc (NURS)?
Revenue at Hydreight Technologies Inc is growing +449% versus a year earlier (3y avg +102%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hydreight Technologies Inc (NURS)?
Earnings per share at Hydreight Technologies Inc are growing +98.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hydreight Technologies Inc (NURS) generate?
The free cash flow of Hydreight Technologies Inc is −C$3.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hydreight Technologies Inc (NURS) carry?
The net debt of Hydreight Technologies Inc is C$522 (fiscal year 2019). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hydreight Technologies Inc in the live analysis

One click puts Hydreight Technologies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.